Vimentin-IN-1
目录号 : GC68437Vimentin-IN-1 是 FiVe1 衍生物，是一种口服有效的选择性抗癌剂。FiVe1 能够结合 III 型中间丝蛋白 vimentin (VIM)，诱导 Ser56 过度磷酸化，导致有丝分裂的选择性中断和转化表达 VIM 的间充质癌细胞的多核化。Vimentin-IN-1 比 FiVe1 表现出更好的口服利用度和药代动力学特征。
Cas No.:2319587-80-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Vimentin-IN-1 is a FiVe1 derivative, an orally active and selective anticancer agent. FiVe1 binds type III intermediate filament protein vimentin (VIM), to induce hyperphosphorylation of Ser56, resulting selective disruption of mitosis and multinucleation in transformed VIM-expressing mesenchymal cancer cells. Vimentin-IN-1 shows better oral bioavailability and pharmacokinetic profiles than FiVe1[1].
Vimentin-IN-1 (compound 4e) (0-10 mM; 72 h) inhibits a marked improvement in potency with an IC50 value of 44 nM against HT-1080 fibrosarcoma, better than than FiVe1 (IC50=1.6 μM, HT-1080)[1].
Vimentin-IN-1 (0.1 μM; 24 h) induces phosphorylation of VIM at Ser56[1].
Vimentin-IN-1 (100 μM; sampled at 0, 5, 15, 30, 45, and 60 min) exhibits poor stability with 0.0% remaining after 60 min of incubation in mouse liver microsome[1].
Cell Viability Assay[1]
| Cell Line: | HT-1080, RD, and MCF-7 cells |
| Concentration: | 0-10 mM |
| Incubation Time: | 72 hours |
| Result: | Inhibited HT-1080, RD, and MCF-7 cells with IC50s of 44 nM, 61 nM, and 49 nM, respectively. |
Vimentin-IN-1 (compound 4e) (10 mg/kg; p.o.; single dose) shows better oral pharmacokinetic properties than Five1[1].
Pharmacokinetic properties of Vimentin-IN-1 in mice[1]
| Route | Dose (mg/kg) | AUC0-last (ng.h/mL) | AUC0-inf (ng.h/mL) | T1/2 (h) | Tmax (h) | Tlast (h) | Cmax (ng/mL) | |
| 4e | PO | 10 | 371.33 | 534.33 | 4.68 | 0.67 | 8 | 154.67 |
| 4e | IP | 1 | 208.33 | 211.33 | 0.59 | 0.25 | 4 | 197.00 |
| Five1 | PO | 25 | 309.78 | 339.21 | 4.57 | 0.5 | 18 | 110.43 |
[1]. MartÍnez-PeÑa F, et al. Synthesis and biological evaluation of novel FiVe1 derivatives as potent and selective agents for the treatment of mesenchymal cancers. Eur J Med Chem. 2022 Nov 15;242:114638.
| Cas No. | 2319587-80-7 | SDF | Download SDF |
| 分子式 | C19H18Cl2N4O | 分子量 | 389.28 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5688 mL | 12.8442 mL | 25.6885 mL |
| 5 mM | 0.5138 mL | 2.5688 mL | 5.1377 mL |
| 10 mM | 0.2569 mL | 1.2844 mL | 2.5688 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet